Products

Get a quote

We're excited to learn more about your project and provide you with a customized quote tailored to your needs. Please fill out the form below, and we'll get back to you as soon as possible.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bovine Cell adhesion molecule L1 like (CHL1) ELISA Kit-Sandwich

Name: Bovine Cell adhesion molecule L1 like (CHL1) ELISA Kit-Sandwich
SKU: EK10F392
Rating: 5 (1 reviews)

Cat. No.EK10F392

Product TypeAnimal Immunoassay Kits

Size

Inquiry Now Add to Inquiry List

Product Overview

BioVenic Bovine CHL1 ELISA Kit-Sandwich is designed for the quantitative determination of Bovine cell adhesion molecule L1 like (CHL1) in serum, plasma, tissue homogenate, cell culture supernatant, cell lysate, and other biological fluids using a Sandwich ELISA method. For research use only.

Specifications

Assay Type ELISA-Sandwich

Specificity The assay kit is specific for Bovine CHL1.

Target Species Bovine

Species Reactivity Bovine

Detection Range 0.2-10 ng/mL

Sensitivity 0.03 ng/mL

Reproducibility Intra-Assay: CV < 10%; Inter-Assay: CV < 10%

Assay Time Around 180 min

Sample Requirement Serum, plasma, tissue homogenate, cell culture supernatant, cell lysate, and other biological fluids.

Target Information

Cell adhesion molecule L1 like is encoded by the CHL1 gene in cattle. It is a cell-adhesion molecule proposed as being a putative tumour-suppressor gene in breast cancer.

Target/Biomarker Bovine CHL1

Target Synonym cell adhesion molecule L1 like; neural cell adhesion molecule L1-like protein; cell adhesion molecule with homology to L1CAM (close homolog of L1)

Gene ID 504415

UniProt ID F1MW33

Shipping and Storage

This product is shipped with gel ice packs. It is recommended to store at 2-8 °C (Up to 6 months).

Documents

Datasheet

COA

To request a Certificate of Analysis, please enter the Lot No. in the search box. Note: Certificate of Analysis not available for kits.

The product is for research use only.
Not for commercial, prophylactic, diagnostic, or therapeutic applications.

References

Martín-Sánchez, E. et al. CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer. Oncotarget. 2017, 8: 15789-15801.